Post-transplantation cyclophosphamide and antithymocyte globulin in 8/10 HLA-mismatched unrelated donor transplantation: the analysis on behalf of the transplant complications working party of the EBMT
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023736%3A_____%2F25%3A00013824" target="_blank" >RIV/00023736:_____/25:00013824 - isvavai.cz</a>
Result on the web
<a href="https://doi.org/10.1038/s41409-025-02678-z" target="_blank" >https://doi.org/10.1038/s41409-025-02678-z</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1038/s41409-025-02678-z" target="_blank" >10.1038/s41409-025-02678-z</a>
Alternative languages
Result language
angličtina
Original language name
Post-transplantation cyclophosphamide and antithymocyte globulin in 8/10 HLA-mismatched unrelated donor transplantation: the analysis on behalf of the transplant complications working party of the EBMT
Original language description
Allogeneic hematopoietic cell transplantation (alloHCT) from 8/10 HLA-matched unrelated donor is performed in a minority of patients. There is little data on its outcomes and consequently, guidelines on optimal transplantation procedures are lacking. The Transplant complications working party of the EBMT performed a registry study comparing approaches to graft-versus-host disease (GVHD) prophylaxis in recipients of alloHCT from 8/10 HLA-mismatched unrelated donors (8/10 MMUD). The analysis included 450 adult patients with hematological malignancies receiving a first alloHCT between 2015 and 2021, GVHD prophylaxis strategies included ATG in 318 and PTCy in 132 patients. AlloHCT from 8/10 MMUD resulted in 21.1% non-relapse mortality, 28.5% cumulative incidence of relapse, 55.7% overall survival (OS), 50.4% progression-free-survival and 39.8% GVHD-relapse-free survival (GRFS). PTCy decreased the risk of grade II-IV (HR 0.63, 95%CI 0.40–0.99) and III–IV acute GVHD (HR 0.31, 95%CI 0.13–0.74), improved OS (HR 0.63, 95%CI 0.41–0.95) and GRFS (HR 0.65, 95%CI 0.47–0.91). No other differences between the groups were documented. Transplantation from female donors to male recipients increased the incidence of extensive chronic GVHD (HR 2.39, 95%CI 1.10–5.19) and decreased PFS (HR 1.49, 95%CI 1.01–2.20). AlloHCT from 8/10 HLA-matched unrelated donor is feasible and the use of PTCy in GVHD prophylaxis improves outcomes.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2025
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Bone marrow transplantation
ISSN
0268-3369
e-ISSN
—
Volume of the periodical
60
Issue of the periodical within the volume
11
Country of publishing house
GB - UNITED KINGDOM
Number of pages
10
Pages from-to
1426-1435
UT code for WoS article
001552522700001
EID of the result in the Scopus database
2-s2.0-105013568793